In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa

Journal of Antibiotics

Volumn 70, Issue 3, 2017, Pages 246-250

  Morinaka, Akihiro ^a   Tsutsumi, Yuko ^a   Yamada, Keiko ^a   Takayama, Yoshihiro ^a   Sakakibara, Shiro ^a   Takata, Toshihiko ^a   Abe, Takao ^a   Furuuchi, Takeshi ^a   Inamura, Seiichi ^a   Sakamaki, Yoshiaki ^a   Tsujii, Nakako ^a   Ida, Takashi ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEPHALOSPORINASE; MEROPENEM; NACUBACTAM; PIPERACILLIN; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; LACTAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; EFFECTIVE CONCENTRATION; EXPERIMENTAL MODEL; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; THIGH; ANIMAL; ANTIBIOTIC RESISTANCE; COMPLICATION; DRUG EFFECTS; GENETICS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEUTROPENIA; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BETA-LACTAMS; HUMANS; LACTAMS; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85014198309     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2016.150     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention Antibiotic resistance threats in the United States, 2013, (Centers for Disease Control and Prevention, Atlanta, GA, 2013).
2. Masuda, N. et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 3322-3327 (2000).
3. Winkler, M. L. et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 59, 1020-1029 (2015).
4. Castanheira, M., Mills, J. C, Farrell, D. J. & Jones, R. N. Mutation-driven [3-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob. Agents Chemother. 58, 6844-6850 (2014).
5. Watkins, R. R., Papp-Wallace, K. M., Drawz, S. M. & Bonomo, R. A. Novel [3-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front. Microbiol. 4, 1-8 (2013).
6. Morinaka, A. et al. OP0595, a new diazabicyclooctane: mode of action as a serine (3-lactamase inhibitor, antibiotic and [3-lactam 'enhancer'. J. Antimicrob. Chemother. 70, 2779-2786 (2015).
7. Bush, K. & Jacoby, G. A. Updated functional classification of [3-lactamases. Antimicrob. Agents Chemother. 54, 969-976 (2010).
8. Zhanel, G. G. et al. Ceftazidime-avibactam: a novel cephalosporins-lactamase inhibitor combination. Drugs73, 159-177 (2013).
9. Livermore, D. M. et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55, 390-394 (2011).
10. Hirsch, E. B. et al. In vitro activity of MK-7655, a novel [3-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob. Agents Chemother. 56, 3753-3757 (2012).
11. Livermore, D. M., Warner, M. & Mushtaq, S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J. Antimicrob. Chemother. 68, 2286-2290 (2013).
12. Livermore, D. M., Mushtaq, S., Warner, M. & Woodford, N. Activity of OP0595/[3-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing [3-lactamases. J. Antimicrob. Chemother. 70, 3032-3041 (2015).
13. Savli, H. et al. Expression stability of six housekeeping genes: a proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. J. Med. Microbiol. 52, 403-408 (2003).
14. Tam, V. H. et al. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin. Microbiol. Infect. 4, 413-418 (2007).
15. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Third Informational Supplement M100-S25, (Clinical and Laboratory Standards Institute, Wayne, PA, 2015).
16. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M7-A10, (Clinical and Laboratory Standards Institute, Wayne, PA, 2015).
17. Clinical and Laboratory Standards Institute Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline M26-A, (Clinical and Laboratory Standards Institute, Wayne, PA, 1999).
18. Craig, W. A. & Andes, D. R. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum [3-lactamases, in the thighs of neutropenic mice. Antimicrob. Agents Chemother. 57, 1577-1582 (2013).
19. Melchers, M. J., van Mil, A. C. & Mouton, J. W. In vitro activity of ceftolozane alone and in combination with tazobactam against extended-spectrum-p-lactamase-harboring Enterobacteriaceae. Antimicrob. Agents Chemother. 59, 4521-4525 (2015).
20. Morinaka, A. et al. In vitro and In vivo activities of OP0595, a new diazabicyclooctane, against CTX-M-15-positive Escherichia coli and KPC-positive Klebsiella pneumoniae. Antimicrob. Agents Chemother. 60, 3001-3006 (2016).
21. Moya, B. et al. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Che-mother. 54, 1213-1217 (2010).
22. Singh, R. et al. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J. Antimicrob. Chemother. 70, 2618-2626 (2015).
23. Louie, A. et al. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob. Agents Chemother. 56, 258-270 (2012).
24. VanScoy, B. et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob. Agents Chemother. 57, 2809-2814 (2013).